



Psyence Group Inc.

Unaudited Condensed Consolidated Interim Financial Statements  
For the three and six months ended September 30, 2023

Expressed in Canadian Dollars

(\$)

## **Management's Responsibility for Financial Reporting**

Notice of no auditor review of interim condensed consolidated interim financial statements.

The accompanying Unaudited Condensed Consolidated Interim Financial Statements of Psyence Group Inc. and its subsidiaries (together the "Company") have been prepared by and are the responsibility of management.

Under National Instrument 51-102, Part 4, sub-section 4.3(3)(a), if an auditor has not performed a review of the interim consolidated financial statements; they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor. The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Canadian Institute of Chartered Professional Accountants ("CICPA") for a review of interim financial statements by an entity's auditor.

The Unaudited Condensed Consolidated Interim Financial Statements have been prepared by management, on behalf of the Board of Directors, in accordance with the accounting policies disclosed in the notes to the Unaudited Condensed Consolidated Interim Financial Statements. Where necessary, management has made informed judgments and estimates in accounting for transactions which were not complete at the Condensed Consolidated Interim Statements of Financial Position date. In the opinion of the management, the Unaudited Condensed Consolidated Interim Financial Statements have been prepared within acceptable limits of materiality and are in accordance with International Accounting Standards 34 – Interim Financial Reporting using accounting policies consistent with International Financial Reporting Standards appropriate in the circumstances.

Management has established processes, which are in place to provide it sufficient knowledge to support management representations that it has exercised reasonable diligence that (i) the Unaudited Condensed Consolidated Interim Financial Statements do not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it is made, as of the date of, and for the periods presented by, the Unaudited Condensed Consolidated Interim Financial Statements and (ii) the Unaudited Condensed Consolidated Interim Financial Statements fairly present in all material respects the financial condition, results of operations and cash flows of the Company, as of the date of and for the periods presented by the Unaudited Condensed Consolidated Interim Financial Statements.

The Board of Directors is responsible for reviewing and approving the Unaudited Condensed Consolidated Interim Financial Statements together with other financial information of the Company and for ensuring that management fulfils its financial reporting responsibilities.

Management recognizes its responsibility for conducting the Company's affairs in compliance with established financial standards, and applicable laws and regulations and for maintaining proper standards of conduct for its activities.

Neil Maresky (signed)  
Chief Executive Officer  
Toronto, Canada  
November 10, 2023

Warwick Corden-Lloyd (signed)  
Chief Financial Officer

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**(Expressed in Canadian Dollars)**

**Condensed Consolidated Interim Statements of Financial Position**

As at September 30, 2023 and March 31, 2023

	Note	As at September 30, 2023 (Unaudited)	As at March 31, 2023 (Audited)
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	5	856,496	2,383,352
Restricted cash	5	40,000	40,000
Other receivables	6	34,449	245,243
Prepays		31,524	107,870
<b>Total current assets</b>		<b>962,469</b>	<b>2,776,465</b>
<b>Non-current assets</b>			
Prepays	7	573,223	579,043
Property and equipment	7	625,810	626,049
Intangible assets	8	18,682	19,942
<b>Total non-current assets</b>		<b>1,217,715</b>	<b>1,225,034</b>
<b>TOTAL ASSETS</b>		<b>2,180,184</b>	<b>4,001,499</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Accounts payable and accrued liabilities	10	1,381,893	2,620,209
Current portion of lease liabilities	13	1,949	2,034
Loan Payable	14	996,495	-
<b>Total current liabilities</b>		<b>2,380,337</b>	<b>2,622,243</b>
<b>Non-current liabilities</b>			
Lease liabilities	13	41,329	45,040
<b>Total non-current liabilities</b>		<b>41,329</b>	<b>45,040</b>
<b>TOTAL LIABILITIES</b>		<b>2,421,666</b>	<b>2,667,283</b>
<b>SHAREHOLDERS' EQUITY</b>			
Share capital	11	21,334,283	20,400,055
Shares to be issued	11	158,400	-
Options reserve	11	1,485,992	1,562,373
Warrants reserve	11	1,572,398	1,406,782
Foreign currency translation reserve		(101,515)	(68,138)
Accumulated Deficit		(24,691,040)	(21,966,856)
<b>TOTAL SHAREHOLDERS' EQUITY</b>		<b>(241,482)</b>	<b>1,334,216</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>		<b>2,180,184</b>	<b>4,001,499</b>

**Nature of operations and going concern (Note 1)**

Approved on behalf of the Board of Directors.

"Dr. Neil Maresky"

Chief Executive Officer and Director

"Jody Aufrichtig"

Executive Chairman and Director

*The accompanying notes are an integral part of the Unaudited Condensed Consolidated Interim Financial Statements*

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**(Expressed in Canadian Dollars)**

**Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss**

For three and six months ended September 30, 2023 and September 30, 2022

	Note	Three months Ending September 30, 2023	Three months Ending September 30, 2022	Six months Ending September 30, 2023	Six months Ending September 30, 2022
<b>Expenses</b>					
Sales and marketing		6,915	122,797	8,867	219,303
Research and development		43,644	41,846	1,172,227	291,258
General and administrative	11,15	(809)	226,417	240,645	425,107
Professional fees and consulting fees	11,15	365,786	563,166	1,204,566	1,146,409
Depreciation and amortization	7,8	23,373	26,997	46,451	39,418
<b>Loss before other items</b>		<b>(438,909)</b>	<b>(981,223)</b>	<b>(2,672,756)</b>	<b>(2,121,495)</b>
<b>Other items</b>					
Other income		180	5,541	5,762	5,541
Interest income		175	2,805	1,496	3,165
Interest expense	14	(37,649)	(10,837)	(37,649)	(10,837)
Accretion expense	13	(274)	(304)	(551)	(632)
Foreign exchange (loss)/gain		(15,210)	(3,383)	(23,325)	(9,507)
Share of gain/(loss) from joint venture	9	1,959	(20,238)	54,131	(53,544)
Loss on impairment of loan to joint venture	9	880	-	(51,292)	-
<b>NET LOSS</b>		<b>(488,848)</b>	<b>(1,007,639)</b>	<b>(2,724,184)</b>	<b>(2,187,309)</b>
<b>Other comprehensive(loss)/income</b>					
Foreign exchange loss on translation		(55,205)	(44,286)	(101,515)	(96,453)
<b>TOTAL COMPREHENSIVE LOSS</b>		<b>(544,053)</b>	<b>(1,051,925)</b>	<b>(2,825,699)</b>	<b>(2,283,762)</b>
<b>Loss per share - basic and diluted</b>	17	<b>(0.00)</b>	<b>(0.01)</b>	<b>(0.02)</b>	<b>(0.03)</b>
<b>Weighted average number of outstanding shares - basic and diluted</b>		<b>132,407,414</b>	<b>85,528,931</b>	<b>129,733,595</b>	<b>85,528,931</b>

The accompanying notes are an integral part of the Unaudited Condensed Consolidated Interim Financial Statements

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**(Expressed in Canadian Dollars)**

**Condensed Consolidated Interim Statements of Changes in Equity**

For six months ended September 30, 2023 and September 30, 2022

	Note	Number of shares	Share capital (\$)	Shares to be issued (\$)	Warrants reserve (\$)	Options reserve (\$)	Foreign currency translation reserve (\$)	Deficit (\$)	Total shareholders' equity (\$)
Opening balance as at April 1, 2023		85,528,931	16,023,565	-	1,329,640	1,215,776	26,798	(15,884,564)	2,711,215
Share based compensation	11	-	-	-	63,950	174,482	-	-	238,432
Other comprehensive income		-	-	-	-	-	(96,453)	-	(96,453)
Net loss		-	-	-	-	-	-	(2,187,309)	(2,187,309)
<b>Balance, September 30, 2023</b>		<b>85,528,931</b>	<b>16,023,565</b>	<b>-</b>	<b>1,393,590</b>	<b>1,390,258</b>	<b>(69,655)</b>	<b>(18,01,873)</b>	<b>665,885</b>

	Note	Number of shares	Share capital (\$)	Shares to be issued (\$)	Warrants reserve (\$)	Options reserve (\$)	Foreign currency translation reserve (\$)	Deficit (\$)	Total shareholders' equity (\$)
Opening balance as at April 1, 2023		123,954,188	20,400,055	-	1,406,782	1,562,373	(68,138)	(21,966,856)	1,334,216
Share based compensation	11	-	-	-	-	(11,010)	-	-	(11,010)
Shares issued for cash, net of issuance costs	11	8,832,405	866,734	-	165,616	-	-	-	1,032,350
Private Placements	11	-	-	158,400	-	-	-	-	158,400
Exercise of RSU's	11	483,570	65,371	-	-	(65,371)	-	-	-
Shares issued on settlement of debt	11	17,691	2,123	-	-	-	-	-	2,123
Other comprehensive income		-	-	-	-	-	(33,377)	-	(33,377)
Net loss		-	-	-	-	-	-	(2,724,184)	(2,724,184)
<b>Balance, September 30, 2022</b>		<b>133,287,854</b>	<b>21,334,283</b>	<b>158,400</b>	<b>1,572,398</b>	<b>1,485,992</b>	<b>(101,515)</b>	<b>(24,691,040)</b>	<b>(241,482)</b>

The accompanying notes are an integral part of the Unaudited Condensed Consolidated Interim Financial Statements

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**(Expressed in Canadian Dollars)**

**Condensed Consolidated Interim Statements of Cash Flows**

For six months ended September 30, 2023 and September 30, 2022

	Note	September 30, 2023	September 30, 2022
Net loss		(2,724,184)	(2,187,309)
<b>Non-cash adjustments</b>			
Depreciation and amortization	7,8	46,451	39,418
Foreign exchange		6,256	(89,331)
Share based compensation	11	(11,010)	238,432
Accretion expense	13	551	632
Interest expense	14	37,615	
Share of (gain)/loss from joint venture	9	(54,131)	53,544
Impairment on loan to joint venture	9	51,292	-
<b>Changes in non-cash working capital</b>			
Other receivables		210,794	(35,247)
Prepaid		82,166	29,086
Accounts payable and accrued liabilities		(1,238,316)	139,243
<b>Cash used in operating activities</b>		<b>(3,592,516)</b>	<b>(1,800,695)</b>
Additions to property and equipment	7	(83,026)	(266,566)
Repayment/(Loan) from/(to) joint venture	9	2,839	(121,770)
<b>Cash used in investing activities</b>		<b>(80,187)</b>	<b>(388,336)</b>
Repayment of lease liabilities	13	(1,506)	(1,620)
Proceeds from share issuance, net of issuance costs	11	1,034,473	-
Proceeds from shares to be issued	11	158,400	-
Proceeds from loan	14	954,480	-
<b>Cash from financing activities</b>		<b>2,145,847</b>	<b>(1,620)</b>
Change in cash and cash equivalents		(1,526,856)	(2,190,651)
Cash and cash equivalents, beginning of period		2,383,352	3,494,638
<b>Cash and cash equivalents, end of period</b>		<b>856,496</b>	<b>1,303,987</b>

*The accompanying notes are an integral part of the Unaudited Condensed Consolidated Interim Financial Statements*

**Notes to the Condensed Consolidated Interim Financial Statements**

**1. Nature of operations and going concern**

Psyence Group Inc. (the “**Company**” or “**PGI**”) is a life science biotechnology company focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. The safety and efficacy of psychedelics will be evaluated through rigorous clinical trials.

The Company’s operations are conducted through Psyence Biomed Corp. (“**PBC**”). PBC is incorporated under the laws of the province of British Columbia, Canada. The Company’s registered office is at 121 Richmond Street West, Penthouse Suite, 1300, Toronto, Ontario M5H 2K1. The Company commenced trading on the Canadian Securities Exchange (“**CSE**”) on January 27, 2021 under the symbol “**PSYG**”.

On January 9, 2023, the Company announced that it had entered into a definitive business combination agreement (the “**Business Combination Agreement**”) with Newcourt Acquisition Corp (NASDAQ: NCAC), a special purpose acquisition company (“**SPAC**”) formed for the purpose of acquiring or merging with one or more businesses (“**Newcourt**”). Newcourt has entered into the Business Combination Agreement with Psyence Biomed Corp., a wholly owned subsidiary of the Company, to create a public company leveraging natural psilocybin in the treatment of palliative care. As of November 09, 2023, the business combination has not closed.

On August 2, 2023, the Company and Newcourt announced the entry into an amended and restated business combination agreement which supersedes the previously announced Business Combination Agreement. On the same day the Company and Newcourt also announced the filing of a registration statement on Form F-4 which contains a preliminary proxy statement/prospectus, with the U.S. Securities and Exchange Commission in connection with the proposed Business Combination

On February 15, 2023, Psyence Australia (Pty) Ltd. (“**Psyence Australia**”) was incorporated in Victoria, Australia as a subsidiary of PBC.

**Going concern**

These Unaudited Condensed Consolidated Interim Financial Statements have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.

As at September 30, 2023 the Company had not yet achieved profitable operations, has accumulated losses of \$24,691,040 (March 31, 2023 - \$21,966,856) since its inception and expects to incur further losses in the development of its business, all of which indicate that a material uncertainty exists that casts significant doubt about the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to conduct its planned business, meet its on-going levels of corporate overhead and discharge its liabilities as they come due. The Company has historically raised funds from the issuance of shares and convertible debentures. The Company’s ability to obtain additional financing is materially uncertain, as there is no assurance that additional funding will be available on a timely basis or on terms acceptable to the Company. This casts significant doubt on the entity’s ability to continue as a going concern.

**2. Basis of presentation**

**Statement of compliance**

These Unaudited Condensed Consolidated Interim Financial Statements have been prepared in accordance with IAS 34 *Interim Financial Reporting* as issued by the International Accounting

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

Standards Board (“IASB”). Accordingly, certain disclosures included in annual financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the IASB have been condensed or omitted and these Unaudited Condensed Consolidated Interim Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements for the year ended March 31, 2023.

The Unaudited Condensed Consolidated Interim Financial Statements were authorized for issue on November 09, 2023 by the directors of the Company.

**Basis of measurement**

These Unaudited Condensed Consolidated Interim Financial Statements have been prepared on an accrual basis, are based on historical costs and are presented in Canadian dollars, unless otherwise noted.

**Functional and presentation currency**

These Unaudited Condensed Consolidated Interim Financial Statements are presented in Canadian Dollars (“CAD \$”), which is also PGI’s functional currency. The functional currency of PGI’s subsidiaries, PBC, and Psyence Therapeutics Corp (“PTC”) is Canadian Dollars, Mind Health (Pty) Ltd, is the Lesotho Loti (“LSL”), Psyence South Africa is South African Rand (“ZAR”), Psyence Jamaica is the Jamaican Dollar (“JMD”), Psyence UK is the Great British Pound (“GBP”) and for Psyence Australia is the United States Dollar (“USD”).

**3. Significant accounting policies**

In addition to the significant accounting policies noted below, these Unaudited Condensed Consolidated Interim Financial Statements and the accompanying notes were prepared using the accounting policies described in Note 3 of the Company’s audited Consolidated Financial Statements for the year ended March 31, 2023.

**Basis of consolidation**

These Unaudited Condensed Consolidated Interim Financial Statements incorporate the accounts of PGI and its subsidiaries. A subsidiary is an entity controlled by PGI and its results are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.

Control exists when an investor is exposed, or has rights, to variable returns from the involvement with the investee and has liability to affect those returns through its power over the investee. Where the Company’s interest is less than 100%, the Company recognizes non-controlling interests.

The subsidiaries of PGI that have been consolidated as of September 30, 2023 are as follows:

<b>Name of entity</b>	<b>Place of incorporation</b>	<b>% Ownership</b>	<b>Accounting method</b>
Mind Health (Pty) Ltd.	Lesotho	100%	Consolidation
Psyence Biomed Corp.	British Columbia	100%	Consolidation
Psyence Therapeutics Corp.	Ontario	100%	Consolidation
Psyence South Africa	South Africa	100%	Consolidation
Psyence Jamaica	Jamaica	100%	Consolidation
Psyence UK	England & Wales	100%	Consolidation
Psyence Australia	Australia	100%	Consolidation

As at September 30, 2023, the Company holds 50% ownership in Good Psyence (Pty) Ltd. which is jointly controlled and accounted for under the equity method.



Inter-company balances and transactions are eliminated upon consolidation.

There was no activity recorded for Psyence Jamaica and Psyence UK.

### **Joint Arrangements**

A joint arrangement represents an arrangement where two or more parties hold joint control. Joint control is deemed to exist under contractual agreement where decisions regarding relevant activities of the arrangement require the unanimous consent of those parties sharing control.

A joint venture is a joint arrangement and represents a company or other entity in which each venturer has an interest, holds joint control and holds rights to the net assets of the entity. Interests in joint ventures are accounted for using the equity method of accounting. The Company does not recognize losses exceeding the carrying value of its interest in joint ventures.

### **Share-based payments**

The Company offers a Restricted Share Unit (“**RSU**”) Plan for directors, officers, consultants and employees which will be settled in common shares of the Company. The RSUs are accounted for as equity instruments whereby the RSUs are initially measured at fair value on the grant date and recognized in the options reserve on the condensed consolidated interim statements of financial position.

- Equity-settled share-based payments to directors, officers and employees are measured at the fair value of the equity instruments at the grant date and are recognized as an expense over the relevant vesting periods with a corresponding credit to options reserve or warrants reserve.
- Equity-settled share-based payments to non-employees are measured at the fair value of the goods or services received or the fair value of the equity instruments granted, if it is determined that the fair value of the goods or services received cannot be reliably measured. The fair value of equity settled share-based payments to non-employees is recorded as an expense at the date the goods or services are received with a corresponding credit to options reserve or warrants reserve.
- The number of equity instruments expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest. After the vesting date, amounts recorded for expired instruments remain in options reserve or warrants reserve.

## **4. Critical accounting estimates and judgements**

When preparing the Unaudited Condensed Consolidated Interim Financial Statements, management undertakes a number of judgments, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgments, estimates and assumptions made by management, and will seldom equal the estimated results.

The judgments, estimates and assumptions applied in the Unaudited Condensed Consolidated Interim Financial Statements, including the key sources of estimation uncertainty, were the same as those applied in the Company’s audited Consolidated Financial Statements for the year ended March 31, 2023.

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

**5. Cash and cash equivalents**

Cash and cash equivalents include the following amounts:

- An amount of \$851,269 unrestricted cash held with chartered banks.
- an amount of \$5,227 held in trust by a brokerage firm as security for foreign currency exchanges.
- an amount of \$40,000 in a guaranteed investment certificate with a bank as collateral for a credit facility agreement with a leading chartered bank in Canada. Amounts are held in restricted cash on the consolidated statement of financial position.

**6. Other Receivables**

Other receivables include the following amounts:

	September 30, 2022	March 31, 2023
	\$	\$
Other receivables	570	36,642
Sales tax receivable	33,879	208,601
<b>Total</b>	<b>34,449</b>	<b>245,243</b>

The Company estimated the expected credit loss on the other receivables to be nominal as at September 30, 2023 and March 31, 2023.

**7. Property, plant and equipment**

\$	Computer equipment	Buildings	Right-of-use asset	Production equipment	Furniture & fixtures	Bulk infrastructure	Total
<b>Cost</b>							
Opening Balance	9,440	415,740	59,169	15,122	23,091	64,100	586,662
Additions	881	237,814	-	25,399	-	-	264,094
Foreign Exchange	(1,048)	(50,473)	(6,441)	(2,205)	(2,513)	(6,976)	(69,656)
<b>At March 31, 2023</b>	<b>9,273</b>	<b>603,081</b>	<b>52,728</b>	<b>38,316</b>	<b>20,578</b>	<b>57,124</b>	<b>781,100</b>
Additions	918	-	-	82,108	-	-	83,026
Foreign exchange	(565)	(36,471)	(3,188)	(2,782)	(1,245)	(3,455)	(47,709)
<b>At September 30, 2023</b>	<b>9,626</b>	<b>566,610</b>	<b>49,540</b>	<b>117,642</b>	<b>19,333</b>	<b>53,669</b>	<b>816,420</b>
<b>Accumulated Depreciation</b>							
Opening Balance	4,388	36,756	5,709	5,254	8,478	14,906	75,491
Charge for the year	2,528	55,618	2,838	10,508	7,425	10,831	89,748
Foreign exchange	(533)	(5,223)	(684)	(802)	(1,086)	(1,860)	(10,188)
<b>At March 31, 2023</b>	<b>6,383</b>	<b>87,151</b>	<b>7,863</b>	<b>14,960</b>	<b>14,817</b>	<b>23,877</b>	<b>155,051</b>
Charge for the year	1,211	28,498	1,311	5,757	3,409	5,005	45,191
Foreign exchange	(393)	(5,431)	(482)	(939)	(915)	(1,472)	(9,632)
<b>At September 30, 2023</b>	<b>7,201</b>	<b>110,218</b>	<b>8,692</b>	<b>19,778</b>	<b>17,311</b>	<b>27,410</b>	<b>190,610</b>
<b>Carrying Value</b>							
<b>At March 31, 2023</b>	<b>2,890</b>	<b>515,930</b>	<b>44,865</b>	<b>23,356</b>	<b>5,761</b>	<b>33,247</b>	<b>626,049</b>
<b>At September 30, 2023</b>	<b>2,425</b>	<b>456,392</b>	<b>40,848</b>	<b>97,864</b>	<b>2,022</b>	<b>26,259</b>	<b>625,810</b>

As at September 30, 2023 amounts totalling \$83,432 (March 31, 2023 - \$1,906) held in production equipment were not yet available for use.

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

As of September 30, 2023 amounts totalling \$573,223 (March 31, 2023 - \$579,043) was recognised in prepaids on the consolidated statement of financial position for a deposit on the purchase of equipment.

**8. Intangible assets**

The Company acquired a domain name and have commissioned additional improvements, which is recognized under intangible assets at cost and it is carried at the amortized value.

<b>Intangible Assets</b>	<b>\$</b>
<b><u>Cost:</u></b>	
Opening Balance	25,212
Additions	-
<b>At March 31, 2023</b>	<b>25,212</b>
Additions	-
<b>At June 30, 2023</b>	<b>25,212</b>
<b><u>Accumulated Amortization:</u></b>	
Opening Balance	(2,749)
Charge for the period	(2,521)
<b>At March 31, 2023</b>	<b>(5,270)</b>
Charge for the period	(1,260)
<b>At June 30, 2023</b>	<b>(6,530)</b>
<b><u>Carrying amount:</u></b>	
At March 31, 2023	19,942
<b>At June 30, 2023</b>	<b>18,682</b>

**9. Investment in Joint Venture**

**Good Psyence (Pty) Ltd.**

On April 7, 2021, the Company through PBC entered into a subscription and shareholders agreement (**the "Joint Arrangement"**) with Goodleaf, whereby the Company and Goodleaf each acquired a 50% share and voting rights in a South African-based SPV called "Good Psyence (Pty) Ltd" incorporated on May 5, 2021. The 50% stake was acquired in exchange for an initial investment of ZAR 50 (\$4) from each party.

The investment in Good Psyence was accounted for as of the effective date of incorporation on May 5, 2021 as a joint venture as the subscription and shareholders agreement establishing joint control was effective from that date.

As of September 30, 2023, a total of \$273,137 (March 31, 2023: \$273,137) has been extended to Good Psyence by the Company. Due to the level of uncertainty associated with the Company's ability to recover its non-interest-bearing loans extended to Good Psyence in the short-term, the total amounts outstanding of \$254,891 (March 31, 2023 - \$220,053) have been deemed to form part of the Company's net investment in the joint venture, equal to the Company's shares of losses exceeding the initial equity investment. The loan was fully impaired as at March 31, 2023 due to the uncertainty of the recoverability of the loan and remained fully impaired as at September 30, 2023.

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

Summarized financial information of Good Psyence is presented below, on a 100% basis:

<b>Selected information as at</b>	<b>September 30, 2023</b>	<b>March 31, 2023</b>
Total assets	176,773	222,795
Total liabilities	482,002	662,901
Net deficit	305,229	440,106

<b>For the six months ended</b>	<b>September 30, 2023</b>	<b>September 30, 2022</b>
Revenues	30,585	50,195
Cost of Sales	(22,184)	(54,936)
Administrative expenses	100,479	(102,347)
Other Comprehensive (Loss)/Income	(618)	-
Net loss and comprehensive loss	108,262	(107,088)

During the six months ended September 30, 2023, the Company recognized amounts totaling \$54,131 (September 30, 2022: (\$53,544)) in the consolidated statements of net loss and comprehensive loss related to the Company's share of gain/(loss) from the joint venture. As at September 30, 2023, the loan receivable balance held in loan to joint venture on the consolidated statements of financial position totaled \$nil (March 31, 2023: \$nil) after recording an impairment of \$51,292 (March 31, 2023: \$53,084) in the consolidated statements of loss and comprehensive loss.

#### **10. Accounts payable and accrued liabilities**

Accounts payable and accrued liabilities include the following amounts:

	<b>September 30, 2023</b>	<b>March 31, 2023</b>
Trade payables	989,978	2,051,534
Accrued liabilities	391,915	568,675
Total	1,381,893	2,620,209

#### **11. Share capital**

##### **Authorized share capital**

Unlimited number of voting common shares without par value.

##### **Issued and outstanding**

<b>Common shares</b>	<b>2023</b>		<b>2022</b>	
	<b>Number</b>	<b>Amount (\$)</b>	<b>Number</b>	<b>Amount (\$)</b>
Opening balance April 1	123,954,188	20,400,055	85,528,931	16,023,565
Issuance of shares in private placement	8,832,405	894,273	-	-
Issuance of shares for RSUs exercise	483,570	65,371	-	-
Issuance of shares for debt settlement	17,691	2,123	-	-
Share issuance costs	-	(27,539)	-	-
Balance as at September 30	133,287,854	21,334,283	85,528,931	16,023,565

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

**Common shares**

***Private placement***

On May 25, 2023 the Company issued 7,775,964 units with a subscription price of \$0.12 in a private placement. The Company received proceeds of \$933,116. Each unit comprises one (1) common share and one-half (0.5) of a common share purchase warrant, with each whole warrant exercisable into an additional common share of the Company at a price of \$0.15 per common share for a period of 18 months from the date of grant.

The fair value of the shares was determined by allocating the gross proceeds to common shares and share purchase warrants using the relative fair market value method of each at the time of the issuance. The relative fair value of the shares was determined using the share price on the date of issuance and the relative fair value of the warrants was determined in accordance with the Black-Scholes valuation model. The fair value of the shares was determined to be \$767,500. The fair value of the warrants was determined to be \$165,616.

On August 21, 2023 the Company issued shares with a subscription price of \$0.12 in a private placement. The Company received proceeds of \$126,773.

In relation to the private placements aforementioned, the Company incurred share issuance costs of \$27,539. The share issuance costs were comprised of \$25,416 of cash settled issuance costs and \$2,123 in equity settled issuance costs.

No shares were issued in the comparative six months.

**Shares to be issued**

Gross proceeds of \$158,400 were received in a private placement. The Company issued the shares with a subscription price of \$0.12. The shares were issued upon closing of the private placement subsequent to quarter end. Refer to subsequent events note.

**Stock Options**

The changes in stock options outstanding during the period ended September 30, 2023 are as follows:

	<b>Period ended September 30, 2023</b>	
	Number of options	Weighted average exercise price (\$)
Outstanding, at beginning of period	9,555,825	0.25
Granted (i)	150,000	0.14
Cancelled / forfeited (ii)	(5,974,924)	0.30
Options outstanding, ending	3,730,901	0.16
Options exercisable, ending	2,289,800	0.16

	<b>Period ended June 30, 2022</b>	
	Number of options	Weighted average exercise price (\$)
Outstanding, at beginning of period	7,958,583	0.30
Granted (iii)	220,000	0.20
Cancelled / forfeited	(1,483,659)	0.30
Options outstanding, ending	6,694,924	0.30
Options exercisable, ending	3,999,349	0.30

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

- (i) On May 25, 2023, the Company granted 150,000 options to a director of the Company with each option exercisable into one common share of the Company at a price of \$0.14 per share until May 25, 2028. Options are to vest 50% at the date of grant and 50% 6 months from the date of grant. The fair value of the options was determined to be \$14,504 on the date of grant using the Black-Scholes option pricing model.
- (ii) During the period ended June 30, 2023, a total of 287,547 options were forfeited due to the termination of services from a consultant of the Company and a total of 5,687,377 options were cancelled by mutual consent with consultants of the Company. In connection with the options forfeited and cancelled, previous share-based payment expenses totaling \$402,732 were reversed under professional fees and consulting fees and general and administrative expenses in the condensed consolidated interim statements of net loss and comprehensive loss.
- (iii) On May 1, 2022, the Company granted 220,000 options to a consultant of the Company with each option exercisable into one common share of the Company at a price of \$0.20 per share until April 30, 2027. Options are to vest 17% 3 months from the date of grant, 17% 12 months from the date of grant, 33% 24 months from the date of grant and 33% 36 months from the date of grant. The fair value of the options was determined to be \$11,846 on the date of grant using the Black-Scholes option pricing model.

The following stock options are outstanding as at September 30, 2023:

Expiry date	Number of options outstanding	Exercise price \$	Weight average remaining life (years)	Number of options exercisable
December 31, 2025	200,000	0.30	2.25	200,000
April 30, 2027	220,000	0.20	3.58	74,800
January 31, 2026	1,220,901	0.17	2.33	-
March 31, 2028	1,940,000	0.14	4.50	1,940,000
My 25, 2028	150,000	0.14	4.66	75,000
	3,730,901		3.62	2,289,800

The fair value of the options was determined at the grant date based on the Black Scholes pricing model, using the following weighted average assumptions:

	Options granted on May 25, 2023	Options granted on May 1, 2022
Numbers issued	150,000	220,000
Share price	0.13	0.085
Expected dividend yield	Nil	Nil
Exercise price	0.14	0.20
Risk-free interest rate	2.60%	2.79%
Expected life	5.00	5.00
Expected volatility	100%	100%
Expiry date	May 25, 2028	April 30, 2027

For the three month and six month periods ending September 30, 2023, \$312,863 and \$217,481 was reversed as an expense under professional fees and consulting fees and general and administrative in the condensed consolidated interim statements of net loss and comprehensive loss based on the

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

vesting terms and forfeiture/cancellation of the options.

For the three month and six month periods ending September 30, 2022, \$203 and \$78,038 was expensed and recorded as share based payments under professional fees and consulting fees in the condensed consolidated interim statements of net loss and comprehensive loss.

**Warrants**

The changes in warrants outstanding during the period ended September 30, 2023 and 2022 are as follows:

	<b>Period ended September 30, 2023</b>	
	<b>Number of warrants</b>	<b>Weighted average exercise price (\$)</b>
Outstanding, at beginning of period	10,714,689	0.30
Granted	3,887,982	0.15
Warrants outstanding, ending	14,602,671	0.26
Warrants exercisable, ending	14,602,671	0.26
	<b>Period ended September 30, 2022</b>	
	<b>Number of warrants</b>	<b>Weighted average exercise price (\$)</b>
Outstanding, at beginning and end of period	8,710,553	0.30
Warrants exercisable, ending	8,710,553	0.30

On May 25, 2023 the Company issued 3,887,982 warrants in a private placement. The fair value was determined to be \$165,616 using a relative fair value method. The assumptions used in the Black-Scholes calculation were as follows: Expected dividend yield – Nil; Exercise Price \$0.15; Risk free interest rate – 2.45%; Expected life – 1.5 years and expected volatility of 100%.

The following warrants are outstanding as at September 30, 2023:

<b>Expiry date</b>	<b>Number of warrants outstanding</b>	<b>Exercise price (\$)</b>	<b>Weight average remaining life (years)</b>
November 25, 2024	3,887,982	0.15	1.16
September 2, 2024	2,122,091	0.30	0.92
December 31, 2023	8,592,598	0.30	0.25
	14,602,671		0.84

**Escrow Securities**

In connection with the Company's listing on the CSE, 12,181,767 common shares and 1,635,431 warrants beneficially owned by certain directors and officers of the Company were placed in escrow with an escrow agent pursuant to an escrow agreement dated January 19, 2021. In connection with the

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

acquisition of PTC on January 15, 2021 an additional 6,795,496 common shares were placed in escrow based on the same terms. These shares and warrants shall be released from escrow as follows:

- 1/10 of escrowed securities to be released on January 27, 2021, the date of listing;
- 1/6 of remaining escrow securities to be released 6 months after the listing date;
- 1/5 of remaining escrow securities to be released 12 months after the listing date;
- 1/4 of remaining escrow securities to be released 18 months after the listing date;
- 1/3 of remaining escrow securities to be released 24 months after the listing date;
- 1/2 of remaining escrow securities to be released 30 months after the listing date; and
- Remaining escrow securities to be released 36 months after the listing date.

As of September 30, 2023, 2,86,586 common shares and 245,313 warrants were held in escrow.

**Restricted stock units (RSUs)**

The changes in RSUs outstanding during the period ended September 30, 2023 and 2022 are as follows:

	<b>Period ended September 30, 2023</b>	
	Number of RSUs	
Outstanding, at beginning of period		5,907,141
Exercised during period (i)(ii)		(483,570)
RSUs outstanding, ending		5,423,570
RSUs exercisable, ending		495,000
	<b>Period ended September 30, 2022</b>	
	Number of RSUs	
Outstanding, at beginning of period		980,516
Issued during the period		1,980,000
RSUs outstanding, ending		2,960,516
RSUs exercisable, ending		828,375

- (i) On September 1, 2022, the Company issued 1,500,000 RSUs to executives, directors, consultants and an employee which are exercisable into common shares of the Company at no additional cost and are to vest as follows:
- 495,000 exercisable on September 1, 2022
  - 495,000 exercisable on September 1, 2023;
  - 510,000 exercisable on September 1, 2024.

The fair value of the RSUs was determined to be \$150,000 based on the fair value of the Company's common shares on the date of the grant. Upon exercise, the Company shall settle RSUs by way of common shares, with one (1) common share issued for every one (1) RSU exercised.

- (ii) On May 1, 2022 the Company issued 480,000 RSUs to a consultant which are exercisable into common shares of the Company at no additional cost and are to vest as follows:



**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

- 160,000 exercisable on May 1, 2023;
- 160,000 exercisable on May 1, 2024;
- 160,000 exercisable on May 1, 2025.

The fair value of the RSUs was determined to be \$40,800 based on the fair value of the Company's share price on the date of the grant. Upon exercise, the Company shall settle RSUs by issuance of common shares in the number equal fair market value at exercise date equal to award value. The expiry date is December 31, 2025.

The RSUs granted are accounted for as an equity instrument whereby share-based payments recognized in the statements of net loss and comprehensive loss are held in options reserve.

During the three month and six month periods ended September 30, 2023, \$97,853 and \$206,470 (September 30, 2022 - \$73,276 and \$96,242) was expensed and recorded as share-based payments under professional and consulting fees and general and administrative in the consolidated interim statements of net loss and comprehensive loss on the vesting of RSUs.

## 12. Segmented information

For the period ended September 30, 2023, management determined that the Company operated only in one segment: development of psilocybin medical and nutraceutical products.

The following is an analysis of non-current assets by geographical location:

<b>Asset location (\$)</b>	<b>September 30, 2023</b>	<b>March 31, 2023</b>
Canada	1,199,033	19,942
Southern Africa (Lesotho and South Africa)	18,682	1,205,092
<b>Non-current segment assets</b>	<b>1,217,715</b>	<b>1,225,034</b>

## 13. Leases

The Company has a lease for land for its production facility in Lesotho. The lease is reflected on the interim consolidated statement of financial position as a right-of-use asset and a lease liability. The land has been used to erect manufacturing and processing facilities. The initial term of the lease is nine years beginning June 1, 2020 and ending May 21, 2029. Thereafter, the Company has the option to renew the lease for a further ten-year period for a maximum of five times total. The incremental borrowing rate and term length used in the calculation of the right-of-use asset and discounted lease liability amounts are 2.5% and 19 years, respectively.

### Lease liability

The continuity of lease liability is as follows:

<b>Lease liability (\$)</b>	<b>2023</b>	<b>2022</b>
<b>Opening Balance, April 1</b>	<b>47,074</b>	<b>55,051</b>
Additions	-	-
Accretion expense	551	632
Lease payments	(1,506)	(1,592)
Foreign exchange	(2,841)	(6,082)
<b>Closing Balance, Septemeber 30</b>	<b>43,275</b>	<b>48,009</b>
Less: current portion	1,949	2,066
<b>Non-current portion of lease liability</b>	<b>41,329</b>	<b>46,003</b>

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

The following table presents the future undiscounted payments associated with the sole lease liability as of September 30, 2023 for the next five years and thereafter:

Future undiscounted payments	\$
2024	3,009
2025	3,052
2026	3,097
2027	3,145
2028	3,195
Thereafter	37,908
<b>Total</b>	<b>53,406</b>

**14. Loan Payable**

On August 21 the Company entered into a loan agreement (the "**Loan Agreement**") via its Australian subsidiary Psyence Australia (Pty) Ltd (the "**Borrower**"), to borrow up to AUD\$1,100,000 by way of a secured loan (the "**Loan**") from RH Capital Finance Co., LLC. The Loan is secured by way of a General Security Agreement and parent company guarantee against the assets of the Borrower and the Company. The loan was granted to the Borrower after it successfully registered its research and development activities with the Australian Federal Government. The Borrower benefits from the Australian Federal Government's Research & Development tax incentive program, which could provide up to a 43.5% rebate on research and development expenses in Australia. The Loan will bear interest at 16% per annum subject to a minimum interest chargeable period of 91 days, and be repayable the earlier of (a) 21 business days after the notice of assessment (in respect of R&D refunds) is issued by the Australian Taxation Office to the Borrower for the financial year ended June 30, 2023 (b) an event of default and (c) 30 November 2023.

\$37,615 in interest expense was incurred during the six months ended September 30, 2023. The loan and all outstanding interest were repaid after quarter end after the Australian Taxation Office refunded 43.5% of expenditure incurred on research and development in Australia for the period ended June 30, 2023.

**15. Transactions with related parties**

All related party transactions are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments. The Company incurred the following transactions with related parties during the period ended September 30, 2023 and 2022:

***Compensation to key management personnel***

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Directors.

Key Management Personnel	Three months Ending September 30, 2023	Three months Ending September 30, 2022	Six months Ending September 30, 2023	Six months Ending September 30, 2022
Short term benefits	180,226	258,575	364,370	483,260

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

Share-based compensation	(5,449)	52,815	150,172	133,688
<b>Total</b>	<b>174,777</b>	<b>311,390</b>	<b>514,542</b>	<b>616,948</b>

Short term benefits consist of consulting fees, payroll and other benefits paid to key management personnel.

**Balances**

As at September 30, 2023, the Company held amounts totaling \$28,111 (September 30, 2022 - \$106,752) in accounts payable and accrued liabilities. These are amounts owing to key management personnel.

**16. Financial instruments and financial risk management**

In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework.

**Credit risk**

Credit risk arises from cash held with banks, other receivables and loan to joint venture. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash by depositing with only reputable financial institutions. The Company also assesses the credit quality of counterparties, taking into account their financial position, past experience and other factors.

**Liquidity risk**

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

As at September 30, 2023, the Company's financial liabilities consist of account payable and accrued liabilities which all have contractual maturity dates within one year.

The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. Historically, the Company's main source of funding has been the issuance of shares for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity or debt funding.

The following table illustrates the contractual maturities of financial liabilities as at September 30, 2023:

Financial Instrument Maturity (\$)	Less than 1 year	2-3 years	4-5 years	After 5 years	Total
Accounts payable and accrued liabilities	1,381,893	-	-	-	1,381,893
Lease liability	3,009	6,149	6,340	37,908	53,135
<b>Total</b>	<b>1,384,902</b>	<b>6,149</b>	<b>6,340</b>	<b>37,908</b>	<b>1,920,532</b>

**Foreign exchange risk**

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

The Company operates internationally and is exposed to foreign exchange risk from the LSL, ZAR, AUD and USD. Foreign exchange risk arises from transactions as well as recognized financial assets and liabilities denominated in foreign currencies.

A 10% adverse change in exchange rate would have resulted in a loss of \$45,320 as at September 30, 2023 (September 30, 2022 - \$24,978).

**Interest rate risk**

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has no significant interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially independent of changes in market interest rates.

**17. Loss per share**

The calculation of basic and diluted loss per common share for the three months ended September 30, 2023 was based on the net loss of \$2,724,184 (September 30, 2022 - \$2,187,309) and a weighted average number of common shares outstanding of 129,733,595 (September 30, 2022 – 85,528,931) calculated as follows:

Earnings per share (\$)	September 30, 2023	September 30, 2022
Basic and diluted loss per share:		
Net loss	(2,724,184)	(2,187,309)
Average number of common shares outstanding	129,733,595	85,528,931
Loss per share – basic and diluted	(0.02)	(0.03)

The diluted weighted average number of common shares does not take into account the effects of stock options and warrants as they would be anti-dilutive for the period ended September 30, 2023 and 2022.

**18. Capital management**

The Company manages its cash, common shares, stock options and warrants as capital. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of natural health business and to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.

The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may attempt to issue new shares, issue new debt, acquire or dispose of assets or adjust the amount of cash and short-term investments on hand.

In order to facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors. Management reviews 12-month forecasts on a regular basis to manage the Company's capital requirements.

**PSYENCE GROUP INC.**  
**Condensed Consolidated Interim Financial Statements (unaudited)**  
**September 30, 2023**  
**(Expressed in Canadian Dollars)**

---

Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company's approach to capital management during the period.

**19. Subsequent events**

The loan agreement with RH Capital Finance Co., LLC was repaid in full on October 5, 2023 when the Company received the research and development rebate of AUS \$1,291,482 (\$1,127,076) from the Australian Taxation office which was utilised to settle the loan payable.

On October 30, 2023, the Company issued 35,810 shares for \$4,297 in relation to private placements. On this same date, the shares to be issued on the balance sheet amounting to 1,320,000 shares were issued (refer to note 11) as well as 2,297,051 common shares which were issued at a price of CAD\$0.12 per common share for a portion of the purchase price of equipment supplied to the Company in relation to the previously announced partnership with Eden Labs.